Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Insurers are cutting coverage for costly GLP-1 weight loss drugs, sparking backlash from advocates who say they're vital for ...

Experts warn that the Trump administration’s new $100,000 fee for H-1B visa applications could worsen healthcare’s workforce ...

Capital Rx, a transparent pharmacy benefit manager, has secured a $400 million investment and is rebranding under the name Judi Health as it expands beyond pharmacy benefits, the company announced on ...

Nearly half of healthcare executives plan to leave their organizations within the next year, according to a recent survey. Such significant turnover puts healthcare organizations at risk for ...

Digital health funding is holding steady — venture capital is flowing, IPOs are reappearing, and megarounds are back in force. Startups in this space have raised $9.9 billion throughout the first ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

At MedCity News’ INVEST Digital Health conference, healthcare experts explored strategies to mitigate automation bias — emphasizing the importance of vendor responsibility, use case-specific ...

Healthcare has been moving steadily out of the clinic and into the home. McKinsey estimates that as much as $265 billion in care (nearly a quarter of all Medicare spending) could shift from facilities ...

Big pharmaceutical companies are boosting their production capacity of branded medications with billions of dollars in new U.S. manufacturing plant construction, but generic drug production still ...